Core Viewpoint - The company is undergoing a continuous innovation transformation, with multiple innovative pipelines being launched internationally, leading to an upward revision of revenue and profit forecasts for 2026 while maintaining profit forecasts for 2025 and 2027 [1] Group 1: Financial Analysis - The revenue projections for 2025, 2026, and 2027 are adjusted to 76.3 billion, 100.3 billion, and 110.4 billion respectively, up from previous estimates of 76.3 billion, 91.0 billion, and 110.4 billion [1] - The net profit attributable to the parent company for 2025, 2026, and 2027 is revised to 11.5 billion, 16.5 billion, and 16.6 billion respectively, compared to earlier estimates of 11.5 billion, 13.8 billion, and 16.6 billion [1] - The corresponding EPS for 2025, 2026, and 2027 is adjusted to 0.44, 0.64, and 0.64 respectively, up from previous estimates of 0.44, 0.53, and 0.64 [1] Group 2: Product Development - The company received a milestone payment of 40 million USD from AbbVie for SIM0500 on February 3, 2026, following a licensing agreement signed in January 2025 [1] - SIM0500 is a humanized TCE tri-antibody targeting two tumor-associated antigens, showing strong T-cell cytotoxic effects against multiple myeloma cells [2] - The FDA granted SIM0500 a fast track designation for use in patients with multiple myeloma who have received at least three prior lines of therapy and are resistant or intolerant to standard treatments [2] Group 3: Strategic Partnerships - Since 2025, the company has successfully licensed four pipelines internationally, including agreements with AbbVie, NextCure, Ipsen, and Boehringer Ingelheim, with potential total payments reaching up to 10.6 billion USD and 10.16 billion EUR [3] - The partnerships with major multinational corporations (MNCs) validate the company's enhanced innovation capabilities and suggest ongoing opportunities for new business development in the future [3]

Core Viewpoint - The company, Xiansheng Pharmaceutical (02096), is intensifying its innovative transformation with multiple innovative pipelines being launched internationally. The revenue and profit forecasts for 2026 have been raised due to the confirmation of upfront and milestone payments, while the 2025 and 2027 profit forecasts remain unchanged. The expected revenues for 2025-2027 are 7.63 billion, 10.03 billion, and 11.04 billion yuan respectively, with net profits of 1.15 billion, 1.65 billion, and 1.66 billion yuan, maintaining a "Buy" rating [1]. Business Analysis - On February 3, 2026, the company announced receiving a recent milestone payment of 40 million USD from AbbVie related to SIM0500 (GPRC5D/BCMA/CD3 tri-antibody). In January 2025, the company signed an overseas licensing option agreement with AbbVie for SIM0500, which includes an upfront payment and potential payments up to 1.055 billion USD, along with tiered royalties based on net sales outside Greater China [1][2]. - SIM0500 is a humanized TCE tri-antibody targeting two tumor-associated antigens, showing promising efficacy. It combines a low-affinity but highly targeted CD3 antibody with two anti-tumor-associated antibodies, GPRC5D and BCMA, demonstrating strong T-cell cytotoxic effects against multiple myeloma (MM) cells. In April 2024, SIM0500 received Fast Track designation from the FDA for patients with relapsed or refractory MM who have received at least three prior lines of therapy [1]. Innovation Transformation - Since 2025, the company has successfully licensed out four pipelines, including: 1. SIM0500 with AbbVie for licensing rights 2. SIM0505 (CDH6ADC) with NextCure, potentially yielding 745 million USD in related payments 3. SIM0613 (LRRC15ADC) with Ipsen, with a total transaction payment potential of 1.06 billion USD 4. SIM0709 (TL1A/IL-23 dual antibody) with Boehringer Ingelheim, which includes an upfront payment of 42 million euros and potential milestone payments up to 1.016 billion euros based on development progress and commercialization [2]. - The successful out-licensing of self-developed pipelines further validates the company's enhanced innovative R&D capabilities, with recognition from major multinational corporations (MNCs). There remains potential for continued new business development (BD) opportunities for numerous self-developed pipelines and innovative ADC platforms in the future [2].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative performance increase of over 15% compared to the benchmark index within the next 6 to 12 months [7]. Core Insights - The company has achieved significant business development (BD) progress, enhancing both the breadth and depth of its self-developed new drugs. Recent collaborations with major pharmaceutical companies indicate a strong pipeline and potential for revenue growth [4]. - The financial forecast predicts total revenue growth from 66.40 billion CNY in 2023 to 104.27 billion CNY by 2027, with a compound annual growth rate (CAGR) of approximately 16% [4][6]. - The net profit attributable to shareholders is expected to rise from 7.15 billion CNY in 2023 to 16.09 billion CNY in 2027, reflecting a significant increase in profitability [4][6]. Financial Summary - Revenue projections for the company are as follows: 6,640 million CNY in 2023, 6,635 million CNY in 2024, 7,690 million CNY in 2025, 9,009 million CNY in 2026, and 10,427 million CNY in 2027, with year-over-year growth rates of 4%, 0%, 16%, 17%, and 16% respectively [3][4]. - The net profit forecast shows a decline of 23% in 2023, followed by a recovery with growth rates of 3%, 63%, 16%, and 16% in the subsequent years [3][4]. - Earnings per share (EPS) are projected to increase from 0.28 CNY in 2023 to 0.62 CNY in 2027, indicating a positive trend in shareholder returns [3][4]. Business Development Highlights - The company has secured multiple partnerships, including a recent agreement with AbbVie for clinical development collaboration, which includes a payment of 40 million USD [4]. - A licensing agreement with Boehringer Ingelheim for a dual-specific antibody is expected to generate up to 1.016 billion EUR in milestone payments, showcasing the company's strong position in the market [4]. - The company is also advancing its ADC (antibody-drug conjugate) pipeline, with significant collaborations that enhance its competitive edge in the industry [4].

Investment Rating - The report suggests focusing on innovative drugs, brain-computer interfaces, and AI medical applications, indicating a positive outlook for these sectors [1]. Core Insights - The pharmaceutical industry index decreased by 3.31% this week, underperforming the CSI 300 index by 3.39 percentage points. However, since the beginning of 2026, the pharmaceutical sector has increased by 3.14%, outperforming the CSI 300 by 1.49 percentage points [5][12]. - The current valuation level (PE-TTM) for the pharmaceutical industry is 29.40 times, with a premium of 61.10% relative to the entire A-share market [22]. - Notable sub-sectors include blood products, which had the best performance this week with a decline of only 1.0%, while the top three performing sectors since the beginning of the year are hospitals (+12.0%), offline pharmacies (+9.3%), and medical R&D outsourcing (+6.7%) [28]. Summary by Sections Investment Strategy - The report highlights a robust combination of companies including 恒瑞医药 (Hengrui Medicine), 百济神州-U (BeiGene), 美好医疗 (Meihua Medical), and others, indicating their potential for growth and investment [19]. Market Performance - The pharmaceutical industry index's performance this week was ranked 23rd, while its year-to-date performance ranked 22nd among all sectors [5][20]. - The report notes that 60 stocks in the pharmaceutical sector had positive returns this week, while 420 stocks declined [35]. Company News - 先声药业 (Xiansheng Pharmaceutical) has authorized勃林格殷格翰 (Boehringer Ingelheim) for its drug SIM0709, with an upfront payment of €42 million and a total deal value of €1.058 billion [13]. - 石药集团 (Shijiazhuang Pharmaceutical) has partnered with 阿斯利康 (AstraZeneca) for a long-acting peptide project, which includes an upfront payment of $1.2 billion and potential milestone payments totaling $3.5 billion [14]. - 同源康 (Tongyuan Pharmaceutical) has its drug TY9591 included in the priority review list, expected to be launched in 2026, targeting EGFR mutation NSCLC brain metastasis patients [15]. Financial Data - The total market capitalization of the pharmaceutical industry is approximately ¥52,861.60 billion, with a circulating market value of ¥48,153.47 billion [3]. - The industry’s TTM PE ratio stands at 37.3, compared to the CSI 300's PE ratio of 14.2, indicating a significant premium for the pharmaceutical sector [3]. Additional Insights - The report emphasizes the importance of innovative drug development and strategic partnerships in driving growth within the pharmaceutical industry, particularly in the context of emerging therapies and technologies [1][19].

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.82 [1][6]. Core Insights - The company has successfully licensed its TL1A/IL-23p19 dual antibody SIM0709 to Boehringer Ingelheim for an upfront payment of €42 million and a total deal value of €1.058 billion, indicating strong validation of its innovative research and development capabilities [1]. - The company has seen recognition from major multinational corporations (MNCs) such as AbbVie, BI, and Ipsen for its innovative pipeline, with four projects launched overseas since 2025 [1]. - The global market for Inflammatory Bowel Disease (IBD) is projected to reach USD 28 billion by 2028, with the TL1A target showing significant potential for treatment [2]. - SIM0709 is designed as a long-acting dual antibody with a potential dosing interval of three months, which could position it favorably in the competitive landscape for IBD treatments [3]. - Boehringer Ingelheim's established global development capabilities are expected to significantly support the global expansion of SIM0709, as it is a key player in the autoimmune disease treatment space [4]. - The company is advancing its innovative platforms, including TCE and ADC, with ongoing clinical trials and collaborations that are expected to yield data within the year [5]. Financial Projections - The company forecasts adjusted net profits of RMB 1.18 billion, RMB 1.40 billion, and RMB 1.52 billion for the years 2025, 2026, and 2027 respectively, reflecting a compound annual growth rate (CAGR) of 14% [6][12]. - The earnings per share (EPS) estimates are projected at RMB 0.45, RMB 0.54, and RMB 0.59 for the years 2025, 2026, and 2027 respectively [6][12]. - The company maintains a price-to-earnings (PE) ratio of 33.19x for 2026, supporting the target price of HKD 19.82 [6][12].

Group 1: Macro Overview - The Federal Reserve maintained the policy interest rate at 3.5-3.75% during the January FOMC meeting, expressing a more optimistic outlook on the economy and job market [2] - The Hang Seng Index and Hang Seng Tech Index both rose over 2.5%, with the Hang Seng Index surpassing 27,800 points, marking a new high since 2021 [2] - The report suggests that the first quarter may be a critical period for the Hong Kong stock market, with potential for further growth driven by liquidity, capital, and earnings [2] Group 2: Utility and Environmental Sector - The carbon pricing market is expected to stabilize after a decline in 2025, with projections indicating a price of 150-200 RMB/ton by 2030 [4] - Companies in the green electricity and environmental sectors, such as Longyuan Power and China Everbright Environment, are expected to benefit from the rising carbon costs and green certificate revenues [4] - Potential catalysts for growth include the introduction of policies linking green certificates to carbon quotas and the expansion of the carbon market [4] Group 3: Key Companies - Disco Corporation is positioned to benefit from the new AI chip generation, with a target price of 79,000 JPY, reflecting a 48x FY26E PE [5] - Xiansheng Pharmaceutical has successfully licensed its dual antibody SIM0709 to Boehringer Ingelheim, validating its innovation system and maintaining a "buy" rating [6] - Industrial Fulian expects a significant increase in net profit for 2025, with projections of 35.1-35.7 billion RMB, driven by the launch of new products and vertical integration advantages [8] - Anta Sports is set to acquire a 29.06% stake in PUMA for approximately 1.506 billion euros, enhancing its global brand portfolio and market presence [8] - Jingwei Hengrun anticipates a turnaround in profitability for 2025, projecting a net profit of 0.75-1.1 billion RMB, supported by scale effects [11] - Ruya Chen expects continued high growth in its self-owned brand business, with a projected net profit of 176-200 million RMB for 2025 [12] - Wancheng Group is expected to improve same-store performance and maintain a rapid store opening pace, supported by supply chain efficiency [13] - Ugreen Technology is focusing on AI and NAS integration, with a projected net profit of 653-733 million RMB for 2025 [14]

Summary of the Conference Call Records Company Overview - **Company**: Xiansheng Pharmaceutical (先声药业) - **Industry**: Biopharmaceuticals, specifically focusing on innovative drug development for inflammatory bowel disease (IBD) Key Points and Arguments Partnership and Collaboration - On January 27, 2026, Xiansheng Pharmaceutical announced a licensing and collaboration agreement with Boehringer Ingelheim to jointly develop the preclinical dual-specific antibody SIM0709 targeting TL1A and IL-23 for the treatment of IBD [1] - Xiansheng Pharmaceutical will receive an upfront payment of €42 million, with potential milestone payments reaching up to €1.016 billion based on development, registration, and commercial success [1] Product Development and Pipeline - SIM0709 is developed from Xiansheng's multi-antibody technology platform and has shown superior efficacy in both in vitro and in vivo studies compared to the combination of two single drugs [2] - The company has 10 approved innovative drugs and over 60 projects in its R&D pipeline, with expectations to approve 2-3 new innovative drugs annually [2] - Upcoming approvals include Enlitaz (injection of rituximab β) and Xianbixin sublingual tablets in 2024, and Enzeshun (injection of suvezatamab, VEGF) and the insomnia treatment Daliresheng in 2025 [2] Business Development and Market Position - As of January 2026, Xiansheng Pharmaceutical has achieved 5 technology licensing agreements for early-stage self-developed innovative drugs, with a total potential transaction value exceeding $4.6 billion [2] - The company has successfully established its ADC (Antibody-Drug Conjugate) and TCE (T-cell Engager) platforms, with ongoing clinical pipeline advancements and business development collaborations [3] Financial Performance and Shareholder Returns - Xiansheng Pharmaceutical maintains a solid core business with high dividend payouts and shareholder returns, indicating strong R&D contributions and potential for upward elasticity [3] Additional Important Information - Over 3 million people globally are affected by inflammatory bowel disease (IBD), highlighting the significant market potential for SIM0709 and similar treatments [2] - The innovative drug matrix of Xiansheng Pharmaceutical is rich, with multiple blockbuster products expected to be approved in the near future, reinforcing the company's growth trajectory [2]

Core Viewpoint - The announcement of an exclusive licensing agreement between the company and Boehringer Ingelheim for the dual-specific antibody SIM0709 has positively impacted the company's stock price, reflecting investor confidence in its innovative capabilities in the autoimmune research field [1] Group 1: Licensing Agreement Details - The company’s subsidiary, Jiangsu Xiansheng, signed an exclusive licensing agreement with Boehringer Ingelheim on January 26, 2026, granting Boehringer global exclusive rights to SIM0709 outside Greater China [1] - The agreement includes an upfront payment of €42 million and potential milestone payments up to €1.016 billion based on development progress, regulatory approvals, and commercialization [1] - The company will also receive tiered royalties on net sales outside Greater China [1] Group 2: Product Information - SIM0709 is a long-acting humanized dual-specific antibody developed by the company’s proprietary multi-specific antibody platform [1] - The antibody targets TL1A and IL-23, which are key pathways involved in the onset and progression of inflammatory bowel disease [1] - Preclinical studies have shown that SIM0709 exhibits superior synergistic effects compared to the combination of two single agents in both in vitro and in vivo experiments [1]

Core Viewpoint - The announcement by the company regarding the exclusive licensing agreement with Boehringer Ingelheim for the dual-specific antibody SIM0709, which targets inflammatory bowel disease, highlights a significant strategic partnership aimed at global development and commercialization opportunities [1] Group 1: Licensing Agreement Details - The agreement grants Boehringer Ingelheim exclusive rights to SIM0709 outside of the Greater China region [1] - The company is entitled to receive an upfront payment of €42 million, with potential milestone payments reaching up to €1.016 billion based on development progress, regulatory approvals, and commercialization [1] - Additionally, the company will receive tiered royalties on net sales outside of Greater China [1] Group 2: Product Development and Market Potential - SIM0709 is developed using the company's multi-antibody technology platform and is considered to have "first-in-class" potential in the treatment of inflammatory bowel disease [1] - The partnership is the company's second overseas licensing project for innovative drugs in the autoimmune disease sector and the fifth self-developed innovative drug project to achieve external technology licensing [1] - The total potential transaction value for the company has exceeded $4.6 billion to date [1] Group 3: R&D Investment and Revenue Growth - The company has been increasing its R&D investment, with the proportion of revenue from innovative drugs rising from 45% in 2020 to 77% by the first half of 2025 [1]

Core Viewpoint - The collaboration between Xiansheng Pharmaceutical and Boehringer Ingelheim aims to develop the dual-specific antibody SIM0709 for the treatment of inflammatory bowel disease, highlighting the potential for innovative therapies in this area [1] Group 1: Partnership Details - Xiansheng Pharmaceutical has entered into an exclusive licensing and collaboration agreement with Boehringer Ingelheim for the development of SIM0709 [1] - Boehringer Ingelheim will acquire global rights outside Greater China for the project [1] - Xiansheng Pharmaceutical will receive an upfront payment and milestone payments that could total up to €1.058 billion, along with royalties on net sales outside Greater China [1] Group 2: Product Development - SIM0709 is developed using Xiansheng Pharmaceutical's multi-antibody technology platform and is considered to have "first-in-class" potential in the treatment of inflammatory bowel disease [1] - The collaboration is expected to leverage Boehringer Ingelheim's extensive experience in global immunotherapy to establish a solid foundation for the global development of SIM0709 [1]